46,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Meloxicam (MLX) is a highly potent, non - steroidal anti - inflammatory drug (NSAID), is used for the treatment of rheumatoid arthritis, osteoarthritis and other joint diseases. However, the gastrointestinal tract (GI T) adverse effects, such as stomachache, indigestion, and patient compliance are weaknesses the oral and injectable MLX administrations. MLX poor water solubility can give rise to many formulation problems that reduce s its therapeutic efficiency and bioavailability. The objective of this study was to develop a transdermal gel formulation of MLX microsponges in order to enhance…mehr

Produktbeschreibung
Meloxicam (MLX) is a highly potent, non - steroidal anti - inflammatory drug (NSAID), is used for the treatment of rheumatoid arthritis, osteoarthritis and other joint diseases. However, the gastrointestinal tract (GI T) adverse effects, such as stomachache, indigestion, and patient compliance are weaknesses the oral and injectable MLX administrations. MLX poor water solubility can give rise to many formulation problems that reduce s its therapeutic efficiency and bioavailability. The objective of this study was to develop a transdermal gel formulation of MLX microsponges in order to enhance the release and the dissolution of MLX which is the limitation for preparation in topical forms. Also skin delivery is an alternative administration for MLX that can minimize GI side effects and improve patient compliance. The microsponges of MLX were prepared by quasi - emulsion solvent diffusion method using e udragit (polymer) and glycerol (plasticizer).
Autorenporträt
Roaa Abdul Hameed Nief ,from Baghdad/Iraq. 1983/8/8. B.Sc. pharmacy (2006), M.Sc.in 2015 from University of Baghdad/College of Pharmacy.